CLINICAL STUDY
Projected life-expectancy gains with statin therapy for individuals with elevated c-reactive protein levels
Gavin J. Blake, MB, MSc, MRCP*,
Paul M. Ridker, MD, MPH*,* and
Karen M. Kuntz, ScD ,*
* Center for Cardiovascular Disease Prevention, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA;
Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, USA
Manuscript received December 5, 2001;
revised manuscript received April 2, 2002,
accepted April 8, 2002.
* Reprint requests and correspondence: Dr. Karen M. Kuntz, Center for Risk Analysis, 718 Huntington Avenue, Boston, Massachusetts, USA.
kmk{at}hsph.harvard.edu
OBJECTIVES: We sought to estimate the potential gains in life expectancy achieved with statin therapy for individuals without overt hyperlipidemia but with elevated C-reactive protein (CRP) levels.
BACKGROUND: Persons with low-density lipoprotein (LDL) cholesterol levels below current treatment guidelines and elevated CRP levels are at increased risk of cardiovascular disease and may benefit from statin therapy.
METHODS: We constructed a decision-analytic model to estimate the gains in life expectancy with statin therapy for individuals without overt hyperlipidemia but with elevated CRP levels. The annual risks of myocardial infarction (MI) and stroke, as well as the efficacy of statin therapy, were based on evidence from randomized trials. Estimates of prognosis after MI or stroke were derived from population-based studies.
RESULTS: We estimated that 58-year-old men and women with CRP levels  0.16 mg/dl but LDL cholesterol <149 mg/dl would gain 6.6 months and 6.4 months of life expectancy, respectively, with statin therapy. These gains were similar to those for patients with LDL cholesterol 149 mg/dl (6.7 months for men and 6.6 months for women). In sensitivity analyses, we identified the baseline risk of MI and the efficacy of statin therapy for preventing MI as the most important factors in determining the magnitude of benefit with statin therapy.
CONCLUSIONS: Our results suggest that individuals with elevated CRP levels, many of whom do not meet current National Cholesterol Education Program guidelines for drug treatment, may receive a substantial benefit from statin therapy. This analysis supports a crucial need for direct intervention trials aimed at subjects with elevated CRP levels.
|
Abbreviations and Acronyms
| | AFCAPS/TexCAPS | | Air Force/Texas Coronary Atherosclerosis Prevention Study | | CAPRIE | | Clopidogrel vs. Aspirin in Patients at Risk of Ischemic Events | | CARE | | Cholesterol and Recurrent Events | | CRP | | C-reactive protein | | HDL | | high-density lipoprotein | | LDL | | low-density lipoprotein | | MI | | myocardial infarction | | WOSCOPS | | West of Scotland Coronary Prevention Study |
|
This article has been cited by other articles:
|
|
|
|
 
H.-B. Leu, C.-P. Lin, W.-T. Lin, T.-C. Wu, and J.-W. Chen
Risk Stratification and Prognostic Implication of Plasma Biomarkers in Nondiabetic Patients With Stable Coronary Artery Disease: The Role of High-Sensitivity C-Reactive Protein
Chest,
October 1, 2004;
126(4):
1032 - 1039.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M Ridker, P. W.F. Wilson, and S. M. Grundy
Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk?
Circulation,
June 15, 2004;
109(23):
2818 - 2825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Willerson and P. M. Ridker
Inflammation as a Cardiovascular Risk Factor
Circulation,
June 1, 2004;
109(21_suppl_1):
II-2 - II-10.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Stauffer, G. L. Hoetzer, D. T. Smith, and C. A. DeSouza
Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy
J Appl Physiol,
January 1, 2004;
96(1):
143 - 148.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schillinger, M. Exner, J. Amighi, W. Mlekusch, S. Sabeti, H. Rumpold, O. Wagner, and E. Minar
Joint Effects of C-Reactive Protein and Glycated Hemoglobin in Predicting Future Cardiovascular Events of Patients With Advanced Atherosclerosis
Circulation,
November 11, 2003;
108(19):
2323 - 2328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Blake and P. M. Ridker
C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?
Am J Physiol Regulatory Integrative Comp Physiol,
November 1, 2003;
285(5):
R1250 - R1252.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schachter
Review: Lipid lowering drugs, inflammation and cardiovascular disease
The British Journal of Diabetes & Vascular Disease,
May 1, 2003;
3(3):
178 - 182.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C.-H. Wang, S.-H. Li, R. D. Weisel, P. W.M. Fedak, A. S. Dumont, P. Szmitko, R.-K. Li, D. A.G. Mickle, and S. Verma
C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle
Circulation,
April 8, 2003;
107(13):
1783 - 1790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Blake and P. M. Ridker
C-reactive protein and other inflammatory risk markers in acute coronary syndromes
J. Am. Coll. Cardiol.,
February 19, 2003;
41(4_Suppl_S):
37S - 42S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M Ridker
Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention
Circulation,
January 28, 2003;
107(3):
363 - 369.
[Full Text]
[PDF]
|
|
|
|
